Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas.
Tschernia NP, Heiling H, Deal AM, Cheng C, Babinec C, Gonzalez M, Morrison JK, Dittus C, Dotti G, Beaven AW, Serody JS, Wood WA, Savoldo B, Grover NS.
Tschernia NP, et al. Among authors: serody js.
J Immunother Cancer. 2023 Aug;11(8):e006959. doi: 10.1136/jitc-2023-006959.
J Immunother Cancer. 2023.
PMID: 37527906
Free PMC article.